SDSuresh Doddapaneni

Suresh Doddapaneni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suresh Doddapaneni has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Hao Zhu

    Office of Clinical Pharmacology Office of Translational Sciences, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA

    2 shared publications
  • Raj Nair

    Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drug, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA

    2 shared publications
  • Alana Chen

    Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA

    1 shared publication
  • Amit Golding

    Division of Rheumatology and Transplant Medicine, Office of Immunology and Inflammation, Office of New Drug, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA

    1 shared publication
  • Anjali Iyer

    Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA

    1 shared publication
  • Anuradha Ramamoorthy

    Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA

    1 shared publication

Latest Publications

  • Open Access

    Human Radiolabeled Mass Balance Studies Supporting New Drugs Approved by FDA Between 2019 and 2023

    by Anuradha Ramamoorthy, Alana Chen, Edwin Chiu Yuen Chow, Daphne Guinn, Anjali Iyer, Sonia Pahwa, Yunzhao Ren, Chinmay Shukla, Suresh Doddapaneni, Zhixia Yan Danielsen

  • Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis

    by Dipak S. Pisal, Yangbing Li, Amit Golding, Raj Nair, Nikolay P. Nikolov, Rajanikanth Madabushi, Hao Zhu, Suresh Doddapaneni, Chandrahas Sahajwalla, Youwei Bi, et al.

    On October 6, 2023, the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation and dosage of Cosentyx® (secukinumab), for the treatment of adult patients with active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and active non‐radiographic axial spondyloarthritis (nr‐axSpA) with objective signs of inflammation. Clinical pharmacokinetics (PK), efficacy, and short‐term placebo‐controlled safety data were available from clinical studies (NCT04156620 and NCT04209205) with the to‐be‐marketed IV formulation using a maintenance dosage 3 mg/kg every 4 weeks (q4w), which was different from the dose approved (1.75 mg/kg q4w). The IV dosage of 3 mg/kg utilized in these two trials resulted in exposures (Cmax,ss) significantly higher than those for the approved subcutaneous (SC) regimens. Further, there is limited long‐term safety information available for this 3 mg/kg q4w IV dose. To address this important limitation, a model‐informed drug development (MIDD) approach was employed to leverage available clinical PK, efficacy, and safety data from the secukinumab development program to identify a maintenance IV dosing regimen, 1.75 mg/kg IV q4w, that better approximated the relevant SC secukinumab exposures for which efficacy and safety have been established. The MIDD analyses were used to support approval of this IV dosing regimen not directly studied in the indications sought for licensure, PsA, AS, and nr‐AxSpA.


  • Open Access

    Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization

    by Qi Liu, Raj Nair, Ruihao Huang, Hao Zhu, Austin Anderson, Ozlem Belen, Van Tran, Rebecca Chiu, Karen Higgins, Jianmeng Chen, et al.

    A randomized, double‐blind, placebo‐controlled study (SAVEMORE trial) provided data to support an Emergency Use Authorization (EUA) of anakinra in hospitalized adults with positive results of direct severe acute respiratory syndrome‐coronavirus 2 viral testing with pneumonia requiring supplemental oxygen (low‐ or high‐flow oxygen) who are at risk of progressing to severe respiratory failure and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR). Currently, the suPAR assay is not commercially available in the United States. An alternative method was needed to identify patients that best reflect the population in the clinical trial selected based on suPAR level ≥ 6 ng/mL at baseline. A machine learning approach based on data from the SAVEMORE trial was used to develop a scoring rule to identify patients who are likely to have a suPAR level ≥ 6 ng/mL at baseline. External validation of the scoring rule was conducted with data from a different trial (SAVE). This clinical scoring rule with high positive predictive value, high specificity, reasonable sensitivity, and biological relevance is expected to identify patients who are likely to have an elevated suPAR level ≥ 6 ng/mL at baseline. As such, it is included in the EUA to identify patients that fall within the authorized population for whom the known and potential benefits outweigh the known and potential risks of anakinra.